AU2014220339B2 — Oral formulation and suspension of an oncology drug
Assigned to Sun Pharmaceutical Industries Ltd · Expires 2016-12-01 · 9y expired
What this patent protects
Provided herein is an oral formulation and suspension of a pharmaceutical composition comprising sonidegib that is useful for treating diseases related to activity of Hedgehog signaling pathway including, for example, cancers of the brain, muscle, skin, and prostate; medulloblast…
USPTO Abstract
Provided herein is an oral formulation and suspension of a pharmaceutical composition comprising sonidegib that is useful for treating diseases related to activity of Hedgehog signaling pathway including, for example, cancers of the brain, muscle, skin, and prostate; medulloblastoma; pancreatic adenocarcinomas; and small-cell lung carcinomas.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.